Preferred Name |
panitumumab |
|
Synonyms |
MOAB ABX-EGF |
|
Definitions |
A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1857" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1857" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000037857 |
|
altLabel |
MOAB ABX-EGF ABX-EGF monoclonal antibody Vectibix clone E7.6.3 monoclonal antibody ABX-EGF ABX-EGF |
|
Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000419640 http://purl.bioontology.org/ontology/PDQ/CDR0000407530 http://purl.bioontology.org/ontology/PDQ/CDR0000417736 http://purl.bioontology.org/ontology/PDQ/CDR0000407531 http://purl.bioontology.org/ontology/PDQ/CDR0000257863 |
|
cui |
C5574911 C0879427 C5441978 C1743549 |
|
Date last modified |
2008-05-27 |
|
definition |
A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1857" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1857" NCI Thesaurus) |
|
Legacy PDQ ID |
10260 |
|
LT |
TRD |
|
NCI ID |
C1857 |
|
notation |
CDR0000037857 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
panitumumab |
|
tui |
T116 T129 T121 |